Hours of Operation/Sample Dropoff

Monday - Friday: 9am-5pm
or call for special arrangements.

We provide a sample drop off freezer if no one is available to take your samples. Instructions and a form are available in the Main lab.

Announcement Archive
Powered by Squarespace

About Us

The Gene Expression and Genotyping Facility was established in 2000 with first generation Affymetrix Microarray technology. In 2004, the Facility saw great expansion in our services with the addition of an Applied Biosystems (ABI) Sequence Detection System to accommodate high throughput realtime PCR, and, although our initial focus was on gene expression applications, our expansion also included resources for genotyping applications, utilizing both the Affymetrix microarray platform and the Applied Biosystems Taqman assay chemistry to interrogate SNPs. Our most recent expansion in 2011, included the latest in Affymetrix technology, the Titan high-throughput Peg system.

More recently, the Core has expanded its services to include nucleic acid quantitation and quality assessment. In this regard, the GEGF has considerable expertise in both isolating and analyzing nucleic acids from formalin-fixed paraffin embedded material. The GEGF also provides support for Next Generation Sequencing, including Library Preparation and Capture using KapaBiosystems, Agilent SureSelect and Illumina TruSeq technologies.

Our Facility houses the latest in liquid handling equipment, including a newly acquired Biomek FX and several Matrix systems. We also utilize an Agilent TapeStation to assess the quality of nucleic acids and library preps in a high throughput mode. Nucleic Acids are quantified using 96-well spectrophotometer, a Qubit or a Nanodrop.

Please Acknowledge our Services

Please Acknowledge the services provided by this Cancer Center Core Facility in your research papers and publications by including this statement:

"This research was supported by the Gene Expression and Genotyping Facility, a component of the Integrated Genomic Shared Resource sponsored by the Case Comprehensive Cancer Center (P30 CA43703)."